Direct-acting Oral Anticoagulants in Dermatologic Surgery

V Cabezas-Calderon; P Bassas Freixas; V García-Patos Briones

doi:10.1016/j.ad.2019.10.002

Direct-acting Oral Anticoagulants in Dermatologic Surgery

Actas Dermosifiliogr (Engl Ed). 2020 Jun;111(5):357-363. doi: 10.1016/j.ad.2019.10.002. Epub 2020 May 14.

[Article in English, Spanish]

Authors

V Cabezas-Calderon¹, P Bassas Freixas², V García-Patos Briones²

Affiliations

¹ Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic address: [email protected].
² Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona, España.

PMID: 32418618
DOI: 10.1016/j.ad.2019.10.002

Abstract

Direct-acting oral anticoagulants (DOACs) have emerged as safer, easier-to-manage alternatives to traditional vitamin K antagonists and are used increasingly because they require no monitoring, have a wider therapeutic window, and react less with other drugs. However, there is little consensus on optimal perioperative management when these drugs are used in dermatologic surgery. This article describes the characteristics of DOACs and reviews current evidence on their use in this setting.

Keywords: Anticoagulación; Anticoagulante oral directo; Anticoagulantes orales directos; Anticoagulation; Cirugía dermatológica; Dermatologic surgery; Direct-acting oral anticoagulant drugs; Direct-acting oral anticoagulants; Hemorragia; Hemorrhage; Hemostasia; Hemostasis.

MeSH terms

Administration, Oral
Anticoagulants* / adverse effects
Dermatologic Surgical Procedures
Factor Xa Inhibitors* / therapeutic use
Fibrinolytic Agents / therapeutic use

Substances

Anticoagulants
Factor Xa Inhibitors
Fibrinolytic Agents